Catalyst for value recognition
Embedded Files
ENIMAXE provides consultancy for developers & advocates of pioneering health technology paving the way to deliver benefits for patients & society
Bridging the Innovation Gap – Because Patients Can’t Wait
Despite remarkable progress in fields like CAR-T therapy and liquid biopsy, too many promising medical innovations are delayed or derailed by complex access barriers, regulatory hurdles, and financing constraints. As a result, patients are left waiting for solutions that often already exist.
For innovators, anticipating these challenges early is critical to:
Secure funding and partnerships
Streamline clinical implementation and regulatory pathways
Build consensus across key stakeholders
Avoid costly delays or market withdrawals altogether
ENIMAXE helps health tech developers stay ahead of the curve. By turning deep cross-sector insights into proactive strategic action, we help increase the predictability and sustainability of investments to close the gap between innovation and real-world impact.
How future-proof is your strategy?
ENIMAXE helps you build your case with the right evidence and stakeholders
Early Value
Assessment
Critical Evidence
Gap Analysis
Multi-stakeholder
Needs & Insights
Value Recognition
Shaping
Why partner with ENIMAXE ?
Expertise in blood-based innovation
In-depth knowledge in the science, history, applications and access challenges for emerging medical technologies within oncology such as:
genomics (CDx, NGS, CGP) for tissue & liquid biopsy (CDx, MRD, MCED, ao)
embolotherapy for interventional oncology
(stem) cell collection (leukapheresis) for
haematopoietic stem cell transplantation (HSCT)
circulating tumor cell-based diagnostics (CTC)
cell & gene therapy (CGT, ATMP) including CAR-T, DLI, DC, ao
International & multilateral engagement
Provides international insights from targeted interviews with diverse stakeholder groups: key-opinion leaders, pioneering researchers, technical lab experts, governmental and regulatory agencies, payers, policy makers, NGO, patient advocacy groups, ao.
Broad background within the medical device, diagnostics and biotech space in oncology, haematology, immunology and pathology across Europe and North America
Quality of scientific due diligence
Comprehensive scientific analysis and communication backed by medical literature, patient data and integrated with multi stakeholder insights.
Constructive focus on existing value versus evidence gaps, to prioritise opportunities to improve processes and fulfil unmet needs, medical and non-medical.
Extensive background of creating clear and visually engaging scientific communication: peer-reviewed publication, white papers, interviews, educational presentations and brochures, literature reviews, publication/medical plans for evidence generation, reimbursement and value dossiers, etc
Durable results for medical technology
Effectively and discretely interacts with fact-based dialogue to inspire key decision-makers to embrace new health technology, to listen and mitigate their concerns, and build a durable solution together.
Track record of scientific engagement resulting in successful adoption of new technology, established best practice with improved patient care & broad consensus for organisation of patient access.
"The ENIMAXE approach treats each stakeholder group as complementary experts, as innovation will become more sustainable and predictable if their needs and insights are integrated early on."
Page updated
Report abuse